Clinical trial of HPV mRNA testing for uterine cervical cancer screening in Kitakyushu city

Cancer research · Cervical cancer

The study demonstrates that HPV mRNA testing can be used as a cervical cancer screening tool, showing a lower positivity rate compared to HPV DNA testing methods.

Background: We investigated the clinical usefulness of HPV (Human Papillomavirus) mRNA testing for uterine cervical cancer screening in Kitakyushu City. Methods: Based on the guidelines, cervical cancer screening through cytology was conducted for women aged 20 and above. Among those screened, HPV mRNA testing (Aptima HPV) was performed on 763 women aged 30–69 years who consented to the screening between 23 June and 06 October 2022. Results: Of the 2456 patients who underwent cervical cancer screening, 24 (0.98%) showed abnormal cytological results: ASC-US (atypical squamous cells of undetermined significance) (9 cases), LSIL (low-grade squamous intraepithelial lesion) (8 cases), HSIL (high-grade squamous intraepithelial lesion) (3 cases), ASC-H (atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion) (3 cases) and AGC (atypical glandular cells) (1 case). Among the 763 individuals who underwent HPV mRNA testing, 35 (4.6%) tested positive for HPV. Statistical analysis revealed a significant difference in HPV mRNA positivity rates across age groups (p < 0.001). The positivity rates were highest in the 30s age group (13.4%) and lowest in the 60s age group (2.2%). The HPV mRNA positivity rate observed in this study was lower compared to HPV DNA testing methods reported in other studies. This suggests that the HPV mRNA test may have different performance characteristics compared to traditional HPV DNA tests. Conclusions: Based on these findings, Kitakyushu City is considering the introduction of HPV mRNA testing for cervical cancer screening, as it may offer a unique perspective on HPV detection and could potentially enhance detection rates and screening coverage.

The findings inform local health authorities about the feasibility and potential advantages of incorporating HPV mRNA testing into routine cervical cancer screening programs, which could improve early detection and optimize resource use.

Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.

Original source

Related signals